Why Merrimack Pharmaceuticals Inc. Rose 38% in September

By Markets Fool.com

Image source: Getty Images.

Continue Reading Below

What happened

Investors in Merrimack Pharmaceuticals(NASDAQ: MACK), a small-cap biotech focused on oncology, had a September to smile about. The company's shares rebounded sharply from their drastic fall in August, risingmore than 38% during the month,according to data fromS&P Global Market Intelligence.

MACK data by YCharts.

So what

Continue Reading Below

Merrimack's shares jumped after script data for August showed that demand for Onivyde --the company's treatment for metastatic pancreatic cancer -- is growing nicely. Gross sales of Onivyde during August came in at $6.1 million, which represents 26% growth over the $4.8 million that was recorded in July.For perspective, Merrimack recorded total gross sales of $14.8 million in the second quarter and $11.3 million in the first.

Now what

Werecentlylearned that Merrimack is going through a massive corporate restructuring in an effort to save money. It laid off 22% of its workforce, and its CEO resigned. The company expects that this move will save more than $200 million over the next two years.

As painful as those cuts were to make, it is understandable why the company decided to take this action. As of the end of thesecond quarter, Merrimack only had $82.7 million in cash on its books. That's a small number when you consider that its quarterly loss was more than $50 million. In addition, the company holds $215 million in long-term debt.

Looking ahead, Merrimack should be hearing soon about Onivyde's approval in Europe. If that goes well, then its international partner,Shire, should be launching the drug soon after. That would be welcome news, and it could go a long way toward helping the company grow its top line.

Still, Merrimack remains in a difficult financial position even after accounting for thecorporaterestructuring. That indicates that a capital raise could be coming soon, which is an unappealing prospect given the company's poor year-to-date performance. For that reason, I'd suggest that potential investors take a pass on this stock for now.

A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him onTwitter where he goes by the handle@Longtermmindsetor connect with him on LinkedIn to see more articles like this.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.